Trial · NCT07155044
A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma
NCT07155044, Active not recruiting, Changhai Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma. Trials, record NCT07155044. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07155044
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma
- NCT number
- NCT07155044
- Status
- Active not recruiting
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Changhai Hospital
- Conditions
- UTUC, UC (Urothelial Cancer)
- Interventions
- NAC
- First posted
- 2025-09-04
- Last updated
- 2025-09-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological Downstaging Rate (≤ ypT1N0) | Assessed at the time of surgery, approximately 10-14 weeks after initiation of treatment for the NAC+Surgery cohort and approximately 2-4 weeks after enrollment for the Surgery Only cohort. | The proportion of patients achieving pathological downstaging to stage ≤ ypT1N0 in the surgical specimen following neoadjuvant chemotherapy and radical nephroureterectomy (RNU), as assessed by central pathology review. Patients in the NAC cohort who do not undergo surgery will be classified as non-responders. |
| Secondary | Pathological Complete Response (pCR) Rate | Assessed at the time of surgery, approximately 10-14 weeks after initiation of treatment. | The proportion of patients achieving a pathological complete response (ypT0N0) in the surgical specimen in the NAC+Surgery cohort. |
| Secondary | Incidence of Treatment-Related Adverse Events | From start of NAC through surgery (approximately 10-14 weeks). | Safety and tolerability of neoadjuvant chemotherapy as measured by the incidence, type, and severity of treatment-related adverse events graded according to CTCAE v5.0. |
| Secondary | Overall Survival (OS) | From enrollment until death from any cause, assessed up to 60 months. | The time from the date of enrollment to the date of death due to any cause. |
| Secondary | Recurrence-Free Survival (RFS) | From surgery until first documented recurrence or death, assessed up to 60 months. | The time from surgery to the first documented occurrence of local/regional recurrence, distant metastasis, or death from any cause, whichever occurs first. |
| Secondary | Cancer-Specific Survival (CSS) | From enrollment until death due to cancer, assessed up to 60 months. | The time from enrollment to death directly attributable to upper tract urothelial carcinoma. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07155044
GET https://conductscience.org/api/trials/v1/NCT07155044/registered